Numinus Announces Listing of Warrants and Change of Trading Symbol for Previously Listed Warrants


Numinus Wellness Inc. (CVE:NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that the TSX Venture Exchange (“TSXV“) has accepted for listing the 16,100,000 common share purchase warrants (the “Warrants“) issued pursuant to the Company’s previously announced prospectus offering that closed on March 19, 2021.

The Warrants will be listed for trading on the TSXV under the symbol “NUMI.WT.C” effective at market open on Tuesday, April 27, 2021.

Each Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $1.75 until March 19, 2023. The Warrants were issued pursuant to, and are governed by, the terms of a warrant indenture dated March 19, 2021 (the “Warrant Indenture“) between the Company and Odyssey Trust Company. A copy of the Warrant Indenture is available under the Company’s SEDAR profile at www.sedar.com.

In addition, the Company announces that the trading symbol for its previously listed common share purchase warrants trading under the symbol “NUMI.WS” will change to “NUMI.WT.B” effective at market open on Monday, April 26, 2021.

About Numinus

Numinus Wellness (TSX-V; NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model – including psychedelic production, supply, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a healthier society.

To view the press release in its entirety, click here.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More